Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary
Summary
We are really excited to have founded Alethiomics and to be recruiting an experienced and dynamic team, enabling us to translate our discoveries in novel target identification into precision medicines to improve the lifespan and quality of life for the patients we care for in the clinic." The breakthrough potential of the founders research is underlined by the fact that work using TARGET-seq, led by Professor Mead, was selected for the Plenary Session at one of most prestigious scientific presentations in haematology; the American Society of Hematology (ASH) annual meeting1. The seed financing will be used to establish Alethiomics research operations at the Oxford BioEscalator, to advance its pipeline of programmes in MPNs, and to industrialise the companys proprietary TARGET-seq drug discovery and target prioritisation platform. Title: Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN Plenary Scientific Session: Hematology Disease Topics & Pathways: Fundamental Science, Genomics, Translational Research, Hematopoiesis, Biological Processes Presenter: Dr Rodriguez-Meira Timing: Presented on Sunday, December 12, 2021, 2:00 PM-4:00 PM EST Paper: https://ash.confex.com/ash/2021/webprogram/Paper150191.html Alethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multi-omic technology to discover and develop life changing treatments for patients with blood cancer. Since 2015, the company has received an automatic stake in all Oxford University science spinouts – and has taken a leading role in creating and building enterprises that address problems that affect people in life-changing ways: their health, the availability of food, the survival of the planet.